-
A low-dose sublingual formulation of Zolpidem has been approved by the FDA for the management of middle-of-the-night (MOTN) awakening. Zolpidem, marketed as Ambien, was originally approved in 1992. The new formulation is marketed by Transcept Pharmaceuticals as Intermezzo.
-
The toxicity associated with intestinal habitation by Clostridium difficile ranges from asymptomatic colonization to life-threatening infection. In the United States, C. difficile is the most common cause of health care-associated diarrhea.
-
-
Combination oral contraceptives (OCs) are the most common form of hormonal contraception used by sexually active females ages 15-19, with 56% of this group reporting ever having used OCs, and 30% reporting use at last intercourse.
-
While pills remain a popular birth control choice, more women are selecting long-acting reversible contraception (LARC), say respondents to the 2011 Contraceptive Technology Update Contraception Survey. More than 80% of respondents say they have seen an increase in LARC methods.
-
A woman comes into your office and says she wants to use an oral contraceptive (OC) for birth control. After confirming that she is a good candidate for the method, when do you start her on her first pack of pills?
-
While combined oral contraceptives (OCs) remain a leading choice for contraception, other methods are making their mark. About 38% of respondents to the 2011 Contraceptive Technology Update Contraception Survey said more than half of their patients use OCs, a drop from 2010's 42% level.
-
New labeling is being eyed regarding increased risks for blood clots for the contraceptive patch and combined oral contraceptives (COCs) containing the progestin drospirenone (DRSP) following recommendations from joint votes from two Food and Drug Administration (FDA) committees.
-
Almost 75% of respondents to the Contraceptive Technology Update 2011 Contraception Survey say they provide advance provision of emergency contraception (EC).
-
